- NCIt
- C4137
Loading cancer entity…
Loading cancer entity…
Clinical trials
32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 |
| Sep 16, 2026 |
| clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06475937 | A Study of DM001 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 128 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical(Suzhou)Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07638371 | FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06894745 | PET [89Zr]DFO-starPEG in Solid Tumors | recruiting | Phase 1 | 13 | Robert Flavell, MD, PhDOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05678010 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | active not recruiting | Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04443088 | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors(KEYNOTE-E12) | recruiting | Phase 1 | 78 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials